Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 13/20 | 1.00 |
| ▸ | NOS1 | P29475 | 11/20 | 1.00 |
| ▸ | NOS3 | P29474 | 7/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.89 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Nil SCHEMBL26908936 | 1.00 | NOS2 (1.00) | NOS2NOS1NOS3CYP1A2TSHR | |
| L-Nil SCHEMBL31294843 | 0.98 | NOS2 (1.00) | NOS2NOS1NOS3CYP1A2TSHR | |
| L-Nil SCHEMBL30703422 | 0.98 | NOS2 (1.00) | NOS2NOS1NOS3CYP1A2TSHR | |
| L-Nio SCHEMBL15944942 | 0.94 | NOS2 (1.00) | NOS2NOS1NOS3CYP1A2TSHR | |
| L-Nio SCHEMBL30007317 | 0.93 | NOS2 (0.96) | NOS2NOS1NOS3CYP1A2TSHR | |
| L-Nio SCHEMBL30728400 | 0.93 | NOS2 (0.96) | NOS2NOS1NOS3CYP1A2TSHR | |
| SCHEMBL29401543 | 0.85 | NOS2 (0.89) | NOS2NOS1NOS3CYP1A2TSHR | |
| SCHEMBL43288 | 0.85 | NOS2 (0.89) | NOS2NOS1NOS3CYP1A2TSHR | |
| SCHEMBL21802133 | 0.85 | NOS2 (0.89) | NOS2NOS1NOS3CYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL25365246 | 0.83 | NOS2 (0.85) | NOS2NOS1NOS3CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| EP-3427061-B1 | USE OF SELECTIVE INOS INHIBITORS FOR TREATING THORACIC AORTIC ANEURYSM | CENTRO NAC DE INVESTIGACIONES CARDIOVASCULARES CARLOS III F S P (ES) | 2023-12-06 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024224296-A2 | TARGETED PHARMACEUTICAL COMPOSITIONS TO TREAT NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-31 | — | — | WO | disclosed |
| EP-3427061-B1 | USE OF SELECTIVE INOS INHIBITORS FOR TREATING THORACIC AORTIC ANEURYSM | CENTRO NAC DE INVESTIGACIONES CARDIOVASCULARES CARLOS III F S P (ES) | 2023-12-06 | — | — | EP | disclosed |